Mexico: These 40 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

Generic name: nepafenac
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2023
Generic Entry Controlled by: Mexico Patent PA05013290
Patent Title: COMPOSICIONES OFTALMICAS QUE CONTIENEN UNA COMBINACION SINERGISTICA DE DOS POLIMEROS. (OPHTHALMIC COMPOSITIONS CONTAINING A SYNERGISTIC COMBINATION OF TWO POLYMERS.)

ILEVRO is a drug marketed by Novartis. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO

See drug price trends for ILEVRO.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the nepafenac profile page.

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Mexico Patent PA05013931
Patent Title: SAL DE ACIDO FOSFORICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA-IV. (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR.)

JANUMET is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JANUMET

See drug price trends for JANUMET.

The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Mexico Patent PA05013931
Patent Title: SAL DE ACIDO FOSFORICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA-IV. (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR.)

JANUMET XR is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUMET XR

See drug price trends for JANUMET XR.

The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

Generic name: sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Mexico Patent PA05013931
Patent Title: SAL DE ACIDO FOSFORICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA-IV. (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR.)

JANUVIA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and one Paragraph IV challenge. Twelve tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUVIA

See drug price trends for JANUVIA.

The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the sitagliptin phosphate profile page.

Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Mexico Patent PA05013931
Patent Title: SAL DE ACIDO FOSFORICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA-IV. (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR.)

JUVISYNC is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JUVISYNC

The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.

Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Mexico Patent PA06000297
Patent Title: DERIVADOS DE PIRIMIDINA-2,4-DIONA COMO ANTAGONISTAS DEL RECEPTOR DE LA HORMONA DE LIBERACION DE GONADOTROPINA. (PYRIMIDINE-2, 4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS.)

ORIAHNN (COPACKAGED) is a drug marketed by Abbvie Inc. There are five patents protecting this drug.

This drug has thirty-eight patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)

The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.

Generic name: elagolix sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Mexico Patent PA06000297
Patent Title: DERIVADOS DE PIRIMIDINA-2,4-DIONA COMO ANTAGONISTAS DEL RECEPTOR DE LA HORMONA DE LIBERACION DE GONADOTROPINA. (PYRIMIDINE-2, 4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS.)

ORILISSA is a drug marketed by Abbvie Inc. There are six patents protecting this drug.

This drug has forty-three patent family members in twenty-four countries. There has been litigation on patents covering ORILISSA

See drug price trends for ORILISSA.

The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.

Generic name: cariprazine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2023
Generic Entry Controlled by: Mexico Patent PA06001033
Patent Title: DERIVADOS DE (TIO) CARBAMOIL-CICLOHEXANO COMO ANTAGONISTAS DEL RECEPTOR D3/D2. ((THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS.)

VRAYLAR is a drug marketed by Allergan. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.

Generic name: insulin aspart; insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Mexico Patent PA06001283
Patent Title: DERIVADOS DE INSULINA NOVEDOSOS. (NOVEL INSULIN DERIVATIVES.)

RYZODEG 70/30 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30

The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.

Generic name: insulin degludec
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Mexico Patent PA06001283
Patent Title: DERIVADOS DE INSULINA NOVEDOSOS. (NOVEL INSULIN DERIVATIVES.)

TRESIBA is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA

See drug price trends for TRESIBA.

The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.

Generic name: insulin degludec; liraglutide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Mexico Patent PA06001283
Patent Title: DERIVADOS DE INSULINA NOVEDOSOS. (NOVEL INSULIN DERIVATIVES.)

XULTOPHY 100/3.6 is a drug marketed by

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6

The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.

Generic name: dabigatran etexilate mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Mexico Patent PA06001959
Patent Title: METANSULFONATO DE ETILESTER DEL ACIDO 3-[(2- {[4-(HEXILOXICARBONILAMINO -IMINO- METIL)-FENILAMINO] -METIL}-1 -METIL-1H- BENCIMIDAZOL-5 -CARBONIL) -PIRIDIN-2-IL -AMINO]-PROPIONICO Y SU UTILIZACION COMO UN MEDICAMENTO. (3-[(2-{[4- (HEXYLOXYCARBONYLAMINO -IMINO-METHYL)- PHENYLAMINO] -METHYL} -1-METHYL -1H.)

PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

Generic name: cabazitaxel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: Mexico Patent PA06002639
Patent Title: SOLVATO ACETONICO DEL DIMETOXI DOCETAXEL Y SU PROCEDIMIENTO DE PREPARACION. (DIMETHOXY DOCETAXEL ACETONE SOLVATE ET METHOD FOR THE PREPARATION THEREOF.)

JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Three tentatively approved generics are ready to enter the market.

This drug has ninety-six patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.

Generic name: telavancin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 22, 2023
Generic Entry Controlled by: Mexico Patent PA06004336
Patent Title: SALES DE CLORHIDRATO DE UN DERIVADO GLICOPEPTIDO FOSFONATO. (HYDROCHLORIDE SALTS OF A GLYCOPEPTIDE PHOSPHONATE DERIVATIVE.)

VIBATIV is a drug marketed by Cumberland Pharms. There are three patents protecting this drug.

This drug has one hundred and twenty-eight patent family members in thirty-five countries.

See drug price trends for VIBATIV.

The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the telavancin hydrochloride profile page.

Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: Mexico Patent PA06004639
Patent Title: PREPARACION SOLIDA QUE COMPRENDE SENSIBILIZADOR DE INSULINA, SECRETAGOGO DE INSULINA Y ESTER DE ACIDOS GRASOS DE POLIOXIETILENO SORBITANO. (SOLID PREPARATION COMPRISING AN INSULIN SENSITIZER, AN INSULIN SECRETAGOGUE AND A POLYOXYETHYLENE SORBITAN FATTY ACID ESTER.)

DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT

See drug price trends for DUETACT.

The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.

Generic name: sapropterin dihydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2023
Generic Entry Controlled by: Mexico Patent PA06005451
Patent Title: METODOS Y COMPOSICIONES PARA EL TRATAMIENTO DE TRASTORNOS METABOLICOS. (TREATMENT OF PHENYLKETONURIAS WITH BH4.)

KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and fourteen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN

See drug price trends for KUVAN.

The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Mexico Patent PA06005581
Patent Title: FORMULACIONES DE PEPTIDOS QUE CONTIENEN PROPILENGLICOL QUE SON OPTIMAS PARA LA PRODUCCION Y USO EN DISPOSITIVOS DE INYECCION. (PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES.)

SAXENDA is a drug marketed by Novo. There are twenty-five patents protecting this drug.

This drug has two hundred and ninety-nine patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA

See drug price trends for SAXENDA.

The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: liraglutide recombinant
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Mexico Patent PA06005581
Patent Title: FORMULACIONES DE PEPTIDOS QUE CONTIENEN PROPILENGLICOL QUE SON OPTIMAS PARA LA PRODUCCION Y USO EN DISPOSITIVOS DE INYECCION. (PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES.)

VICTOZA is a drug marketed by Novo Nordisk Inc. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-seven patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA

See drug price trends for VICTOZA.

The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.

Generic name: latanoprostene bunod
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Mexico Patent PA06007678
Patent Title: NITROXIDERIVADOS DE PROSTAGLANDINAS. (PROSTAGLANDIN NITROOXYDERIVATIVES.)

VYZULTA is a drug marketed by Bausch And Lomb. There are four patents protecting this drug.

This drug has fifty-three patent family members in thirty-eight countries.

See drug price trends for VYZULTA.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Mexico Patent 2,007,006,120
Patent Title: METODO Y COMPOSICION PARA ADMINISTRAR A UN SUJETO UN ANTAGONISTA DEL RECEPTOR DE NMDA. (COMPOSITION COMPRISING A SUSTAINED RELEASE COATING OR MATRIX AND AN NMDA RECEPTOR ANTAGONIST, METHOD FOR ADMINISTRATION SUCH NMDA ANTAGONIST TO A SUBJECT.)

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Mexico Patent 2,007,012,374
Patent Title: METODOS Y COMPOSICIONES PARA EL TRATAMIENTO DE CONDICIONES RELACIONADAS CON CNS. (METHODS AND COMPOSITIONS FOR TREATMENT OF CNS DISORDERS.)

NAMZARIC is a drug marketed by Allergan. There are twelve patents protecting this drug and three Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Mexico Patent PA06008606
Patent Title: MODULADORES DE TRANSPORTADORES CON CASETE DE UNION A ATP. (MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS.)

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and forty-eight patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: omega-3-carboxylic acids
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2024
Generic Entry Controlled by: Mexico Patent PA06008352
Patent Title: UNA COMPOSICION FARMACEUTICA. (A PHARMACEUTICAL COMPOSITION.)

EPANOVA is a drug marketed by Astrazeneca. There are seven patents protecting this drug.

This drug has eighty-four patent family members in forty countries.

The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.

Generic name: ospemifene
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2024
Generic Entry Controlled by: Mexico Patent PA06009546
Patent Title: FORMULACIONES SOLIDAS DE OSPEMIFENO. (SOLID FORMULATIONS OF OSPEMIFENE.)

OSPHENA is a drug marketed by Duchesnay. There are eight patents protecting this drug.

This drug has ninety-four patent family members in thirty-one countries. There has been litigation on patents covering OSPHENA

See drug price trends for OSPHENA.

The generic ingredient in OSPHENA is ospemifene. There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ospemifene profile page.

Generic name: aliskiren hemifumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: Mexico Patent 347,617
Patent Title: FORMULACIONES GALENICAS DE COMPUESTOS ORGANICOS. (GALENIC FORMULATIONS OF ORGANIC COMPOUNDS.)

TEKTURNA is a drug marketed by Noden Pharma. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA

See drug price trends for TEKTURNA.

The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.

Generic name: etonogestrel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: Mexico Patent PA06010714
Patent Title: DISPOSITIVO DE SUMINISTRO DE FARMACOS VISIBLE A TRAVES DE RAYOS-X. (X-RAY VISIBLE DRUG DELIVERY DEVICE.)

IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.

This drug has thirty-two patent family members in twenty-six countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.

Generic name: teriparatide recombinant human
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Mexico Patent PA06011230
Patent Title: APARATO DISPENSADOR DE MEDICACION CON CONFIGURACION DE CIERRE ACCIONADO POR RESORTE HABILITADO POR ADMINISTRACION DE DOSIS FINAL. (MEDICATION DISPENSING APPARATUS WITH SPRING-DRIVEN LOCKING FEATURE ENABLED BY ADMINISTRATION OF FINAL DOSE.)

FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.

Generic name: dienogest; estradiol valerate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Mexico Patent PA06012213
Patent Title: PREPARADO POLIFASICO PARA LA CONTRACEPCION A BASE DE UN ESTROGENO NATURAL. (MULTI-PHASE CONTRACEPTIVE PREPARATION BASED ON A NATURAL ESTROGEN.)

NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

Generic name: umeclidinium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Mexico Patent PA06012405
Patent Title: ANTAGONISTAS DEL RECEPTOR ACETILCOLINA MUSCARINICO. (MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS.)

INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

Generic name: dacomitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Mexico Patent PA06012756
Patent Title: 4-FENILAMINO-QUINAZOLIN-6-IL-AMIDAS. (4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES.)

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety patent family members in forty-seven countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

Generic name: indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Mexico Patent PA06013081
Patent Title: DISPOSITIVO INHALADOR. (INHALER DEVICE.)

ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eighty-six patent family members in thirty-nine countries. There has been litigation on patents covering ARCAPTA NEOHALER

See drug price trends for ARCAPTA NEOHALER.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Mexico Patent PA06013081
Patent Title: DISPOSITIVO INHALADOR. (INHALER DEVICE.)

UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON

See drug price trends for UTIBRON.

The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.

Generic name: elvitegravir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: Mexico Patent PA06013405
Patent Title: CRISTAL ESTABLE DEL COMPUESTO 4-OXOQUINOLINA. (STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND.)

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.

This drug has eighty-three patent family members in thirty-five countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

Generic name: vandetanib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Mexico Patent PA06013501
Patent Title: COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN ED6474. (PHARMACEUTICAL COMPOSITIONS COMPRISING ZD6474.)

CAPRELSA is a drug marketed by Genzyme Corp. There are three patents protecting this drug.

This drug has one hundred and forty-two patent family members in forty-three countries.

See drug price trends for CAPRELSA.

The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.

Generic name: chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 25, 2024
Generic Entry Controlled by: Mexico Patent PA06013481
Patent Title: COMPOSICION DE SUSPENSION FARMACEUTICA. (PHARMACEUTICAL SUSPENSION COMPOSITION.)

CHILDREN'S ADVIL ALLERGY SINUS is a drug marketed by Glaxosmithkline. There is one patent protecting this drug.

This drug has nine patent family members in eight countries.

The generic ingredient in CHILDREN'S ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Mexico Patent PA06013711
Patent Title: FORMULACION DE TABLETA REVESTIDA Y METODO. (COATED TABLET FORMULATION AND METHOD.)

KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

Generic name: saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Mexico Patent PA06013711
Patent Title: FORMULACION DE TABLETA REVESTIDA Y METODO. (COATED TABLET FORMULATION AND METHOD.)

ONGLYZA is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.

Generic name: rifamycin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 25, 2024
Generic Entry Controlled by: Mexico Patent PA06014698
Patent Title: COMPOSICIONES FARMACEUTICAS ANTIMICROBIANAS ORALES. (ORAL ANTIMICROBIAL PHARMCEUTICAL COMPOSITIONS.)

AEMCOLO is a drug marketed by Redhill. There are four patents protecting this drug.

This drug has twenty-eight patent family members in twenty-one countries.

See drug price trends for AEMCOLO.

The generic ingredient in AEMCOLO is rifamycin. There are eleven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the rifamycin profile page.

Generic name: tapentadol hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: Mexico Patent PA06014741
Patent Title: FORMAS CRISTALINAS DE CLORHIDRATO DE (-) - (1R,2R) -3- (3-DIMETILAMINO-1-ETIL-2-METILPROPIL)FENOL. (CRYSTALLINE FORMS OF (-)-(1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)-PHENOL HYDROCHLORIDE.)

NUCYNTA is a drug marketed by Collegium Pharm Inc. There are nine patents protecting this drug and four Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has eighty-three patent family members in thirty-four countries. There has been litigation on patents covering NUCYNTA

See drug price trends for NUCYNTA.

The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

Generic name: tapentadol hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: Mexico Patent PA06014741
Patent Title: FORMAS CRISTALINAS DE CLORHIDRATO DE (-) - (1R,2R) -3- (3-DIMETILAMINO-1-ETIL-2-METILPROPIL)FENOL. (CRYSTALLINE FORMS OF (-)-(1R,2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)-PHENOL HYDROCHLORIDE.)

NUCYNTA ER is a drug marketed by Collegium Pharm Inc. There are nine patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has three hundred and fifty-two patent family members in thirty-seven countries. There has been litigation on patents covering NUCYNTA ER

See drug price trends for NUCYNTA ER.

The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.

Generic name: perampanel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2024
Generic Entry Controlled by: Mexico Patent PA06014458
Patent Title: CRISTAL DEL COMPUESTO DE 1,2-DIHIDROPIRIDINA Y METODO PARA PRODUCIR EL MISMO. (CRYSTAL OF 1,2-DIHYDROPYRIDINE COMPOUND AND METHOD FOR PRODUCING SAME.)

FYCOMPA is a drug marketed by Eisai Inc. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has one hundred and one patent family members in thirty-three countries.

See drug price trends for FYCOMPA.

The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the perampanel profile page.